The pharmacokinetics and bioequivalence of Gengraf and Neoral in stable renal tranplant recipients

Hong Kong Journal of Nephrology

Volumn 5, Issue 1, 2003, Pages 40-43

  Tsang, Wai Kay ^a   Wong, Sze Ho ^a   Chu, Kwok Hong ^a   Lee, William ^a   Cheuk, Au ^a   Tang, Hon Lok ^a   Fung, Samuel Ka Shun ^a   Chan, Hilda Wai Han ^a   Tong, Kwok Lung ^a  

^a PRINCESS MARGARET HOSPITAL   (Hong Kong)

Author keywords

Bioequivalence; Cyclosporine; Gengraf; Pharmacokinetics

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE;

ADULT; AGED; ALLOGRAFT; AREA UNDER THE CURVE; ARTICLE; BIOCHEMISTRY; BIOEQUIVALENCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG FORMULATION; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; EXPERIMENTAL DESIGN; FEMALE; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT;

EID: 0842322854     PISSN: 15615413     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1561-5413(09)60102-2     Document Type: Article

References (10)

1. Tsang WK, Ho YW, Tong KL, Chan WH, Chan A. Safety, tolerability, and pharmacokinetics of Sandimmune Neoral: conversion study in stable renal transplant recipients. Transplant Proc 1996;28:1330-2.
2. Shah MB, Martin JE, Schroeder TJ, First MR. The evaluation of the safety and tolerability of two formulations of cyclosporine: Neoral and Sandimmune. A meta-analysis. Transplantation 1999;67:1411.
3. Mahalati K, Belitsky P, Kiberd BA, West K, Fraser A, Macdonald AS, AcAlister V, Lawen J. Absorption profiling-a novel method for monitoring Neoral in kidney transplantation that reduces rejection and nephrotoxicity. Transplantation 2000;69(Suppl):S114.
4. Mahalati K, Belitsky P, Sketris I, West K, Panek R. Neoral monitoring by simplified sparse sampling area under the concentration time curve. Transplantation. 1999;67:55-62.
5. 0-4 in stable renal allograft recipients. Hong Kong J Nephrol 2001;2:15.
6. Barama A, Perner F, Beauregard-Zollinger L, Prestele H. Absorption profiling of cyclosporine therapy for de novo kidney transplantation: a prospective, randomized study comparing sparse sampling to trough monitoring. Transplantation 2000;69(Suppl):S162.
7. Roza A, Tomlanovich S, Merion R, Pollak R, Wright F, Rajagopalan P, Pruett T, Scandling J, Ryan J, Awni W, Schweitzer S, Greco R, Lam W, Nabulsi A, Hoffman R. Conversion of stable renal allograft recipients to a bioequivalent cyclosporine formulation. Transplantation 2002;74:1013-7.
8. Food and Drug Administration (FDA). Bioavailability and bioequivalence requirements. Fed Register 1992;57:17997.
9. Wahlberg J, Wilczek HE, Fauchald P, Nordal KP, Heaf JG, Olgaard K, Hansen JM, Lokkegarrd H, Mueller E, Kovarik JM. Consistent absorption of cyclosporine from a microemulsion formulation assessed in stable renal transplant recipients over a one-year study period. Transplantation 1995;60:648-52.
10. Kahan BD, Welsh M, Schoenberg L, Rutzky LP, Katz SM, Urbauer DL, Van Buren CT. Variable oral absorption of cyclosporine. Transplantation 1996;62:599-606.